News Updates
Scope
Catalyst

Tue, Apr 21, 2026

2 updates
RHHBY
7:15 PM

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple sclerosis (RMS) Both studies showed positive trends in reducing disability progression with fenebrutinib compared to teriflunomide Fenebrutinib could become a...

Trial Results • Phase 3roche.com
RHHBY
11:45 AM

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) MOGAD is a rare autoimmune disease of the central nervous system characterised by unpredictable attacks of the optic nerves, spinal cord or brain that are often severe and debilitating Data will be submitted to...

Trial Results • Phase 3roche.com